Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Retrieved on:
Tuesday, December 14, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Forward-looking statement, Instagram, LinkedIn, Adoptive cell transfer, U.S. Securities and Exchange Commission, Melanoma, Research, Cancer, HLA, Cell, TCR, Clinical trial, CTA, Paul Ehrlich Institute, NYSE, Private Securities Litigation Reform Act, PEI, Celgene, Annual report, NASDAQ, Risk, SEC, Head, Neoplasm, Goal, Patient, Security (finance), Terminology, Sumathi Best Television Current Reporting Award, Development, Bristol Myers Squibb, Multimedia, Program, Cell therapy, YouTube, Twitter, Hart–Scott–Rodino Antitrust Improvements Act, BMY, Sarcoma, Senior, Pharmaceutical industry, Vaccine, Facebook, IMA401, TCER®, Bristol Myers Squibb, Immatics, IMA401, TCER®, BRISTOL MYERS SQUIBB, IMMATICS
In November 2021, Immatics filed a Clinical Trial Application (CTA)1 with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401.
Key Points:
- In November 2021, Immatics filed a Clinical Trial Application (CTA)1 with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401.
- We are delighted to extend our existing collaboration with Bristol Myers Squibb to the IMA401 program and view this as an important validation of the therapeutic potential of our TCER approach.
- Bristol Myers Squibbs global clinical development and commercialization capabilities in oncology make them the ideal partner for the further development of IMA401.
- We are pleased to expand our collaboration with Immatics to now include IMA401, said Teri Foy, Senior Vice President, Research and Early Development, Immuno-Oncology and Cell Therapy at Bristol Myers Squibb.